Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA blesses Pfizer's Lyrica for spinal cord injury pain

This article was originally published in Scrip

Executive Summary

Pfizer has racked up another US approval for Lyrica (pregabalin), one of its top-selling medicines, this time expanding the labeling to include management of neuropathic pain associated with spinal cord inury, which can be severely debilitating and may significantly hinder rehabilitation and the ability to regain function.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017836

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel